Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 12, 2017
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Wagner Zago, PhD, as Chief Scientific Officer (CSO). Dr. Zago, wh...
May 16, 2017
DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Sarah Noonberg, MD, PhD, as Chief Medical Officer. Dr. Noonberg ...
May 9, 2017
Net cash used in operating and investing activities was $40.2 million in the first quarter; quarter-end cash and restricted cash position of $510.6 million, including net proceeds of $150.3 million raised through March 2017 public equity offering, provides funding to advance R&D pipelineCompleted enro...
May 2, 2017
DUBLIN, Ireland, May 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the first quarter of 2017 on May 9, 2017 after the close of the U.S. financial ...
Apr 26, 2017
DUBLIN, Ireland, April 26, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Deutsche Bank 42nd...
Apr 2, 2017
All dose levels of PRX002/RG7935 found to have an acceptable safety and tolerability profile, meeting the primary objective of this studyRobust central nervous system (CNS) penetration demonstrated by a dose-dependent increase in PRX002 levels in cerebrospinal fluid (CSF), and mean concentrati...
Mar 9, 2017
Investor webcast planned for April 2, 2017 at 9:00 AM EDT to discuss Phase 1b study results  Prothena and Roche to co-host symposium on alpha-synuclein pathology and non-motor manifestations in Parkinson's disease on March 31, 2017 at 5:15 CET DUBLIN, I...
Mar 3, 2017
DUBLIN, Ireland, March 03, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has sold 2,700,000 of its ordinary shares at a price to the public of $57...
Mar 2, 2017
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has commenced a registered underwritten public offering of 2,700,000 of its ordinary shar...
Feb 14, 2017
Net cash used in operating and investing activities was $41.1 million in the fourth quarter and $133.9 million for the full year 2016; year-end cash and restricted cash position of $391 million supports advancement of clinical pipeline         Pre...
Feb 8, 2017
DUBLIN, Ireland, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Lee...
Feb 1, 2017
DUBLIN, Ireland, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2016 financial results on Tue...
Jan 4, 2017
DUBLIN, Ireland, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the 35th A...
Dec 15, 2016
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Carol D. Karp as Chief Regulatory Officer. Ms. Karp will lead P...
Dec 13, 2016
DUBLIN, Ireland, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced the ...
Page:
...
Next Last
 
= add release to Briefcase